India Price Regulator Wants At Least Five Drug Makers Charged
This article was originally published in PharmAsia News
India's regulator of drug prices has called for legal action against five pharmaceutical companies on charges they violated price controls. The National Pharmaceutical Pricing Authority said the companies collectively sold 39 specified pack sizes of different drugs without prior approval of the prices. The firms named were Alembic, Cadilla Healthcare, Medley Pharmaceuticals, Lupin and Wockhardt. The NPPA said it also is looking at nearly 30 other cases of alleged overcharges and is asking the firms involved to repay the excess amounts. It asked state governments to begin prosecution proceedings. (Click here for more
You may also be interested in...
TOKYO - An ad hoc study commission debating prevention of recurring drug-induced hepatitis and HIV infections has recommended creating an independent entity that would supervise pharmaceutical approvals, drug safety and adverse events in an effort to toughen Japanese new drug approval processes
The independent, neutral body would be charged with monitoring, inspecting and investigating MHLW, the Pharmaceutical and Medical Devices Agency and other government administrative functions.
TOKYO - Osaka, Japan-based Mitsubishi Tanabe Pharma reported May 7 ¥9.1 billion ($87.5 million) in special losses for fiscal 2007 due to pending damages suits over its tainted blood products that caused hepatitis C. The company, which was established in October 2007 through a merger between Tanabe Seiyaku Co. and Mitsubishi Pharma, said the sum has been set aside as a provision for possible payments to settle such suits. Mitsubishi Pharma was the successor to defunct blood products maker Green Cross Corp., which sold the virus-tainted blood products, Japanese Kyodo News Agency said in a report